Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorTriangulo Mineiro Federal University—UFTM-
Autor(es): dc.creatorCampos, Débora Leite-
Autor(es): dc.creatorDemarqui, Fernanda Manaia-
Autor(es): dc.creatorSolcia, Mariana Cristina-
Autor(es): dc.creatorde Souza, Paula Carolina-
Autor(es): dc.creatorda Silva Maia, Pedro Ivo-
Autor(es): dc.creatorDeflon, Victor Marcelo-
Autor(es): dc.creatorPavan, Fernando Rogério-
Data de aceite: dc.date.accessioned2025-08-21T21:52:43Z-
Data de disponibilização: dc.date.available2025-08-21T21:52:43Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-10-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/biomedicines10102398-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/249301-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/249301-
Descrição: dc.descriptionAs a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESP-
Descrição: dc.descriptionInstitute of Exact Natural Sciences and Education Triangulo Mineiro Federal University—UFTM-
Descrição: dc.descriptionTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESP-
Descrição: dc.descriptionCNPq: 303603/2018-6-
Idioma: dc.languageen-
Relação: dc.relationBiomedicines-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectlatent tuberculosis-
Palavras-chave: dc.subjectMycobacterium tuberculosis-
Palavras-chave: dc.subjecttreatment-
Título: dc.titleLatent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.